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Introduction
Current antiretroviral therapy (ART) suppresses human immunodeficiency virus type 1 (HIV) RNA in blood and semen to below the level of detection in most infected men, substantially decreasing the risk of sexual HIV transmission [1] [2] [3] [4] . Recent studies reported a >90% reduction in HIV transmission among serodiscordant heterosexual couples after starting ART [2, 3] , and a similar reduction in HIV transmission associated with anal intercourse was noted in men who have sex with men (MSM) receiving ART [5] .
Nevertheless, sexual HIV transmission [6, 7] , and intermittent seminal HIV shedding [8] can occur despite ART. The frequency of seminal HIV shedding in treated individual range from 2 to 48% [9] [10] [11] [12] . HIV shedding in the semen of ART-treated individuals might be a consequence of viral compartmentalization [13] with poor drug penetration within the genital tract [8, 14] , or stimulation of virus replication by concurrent sexually transmitted infections (STIs) and genital inflammation [9, 10, [15] [16] [17] . Seminal cytomegalovirus (CMV) was previously associated with increased activation of CD4+ T-cells in the genital tract [18] , and several groups have described an association between CMV and Epstein-Barr virus (EBV) with HIV seminal shedding in individuals with detectable HIV in blood plasma [19] [20] [21] [22] [23] . From a public health perspective, it is crucial to understand if concurrent CMV and EBV shedding are associated with HIV shedding in semen of immunologically reconstituted and virologically controlled individuals.
Materials and Methods

Participants, samples and clinical laboratory tests
Semen samples from asymptomatic chronically HIV-infected high-risk sexual active MSM that were prospectively enrolled in the California Collaborative Treatment Group (CCTG) 592 were included in this study. CCTG 592 is a study of an internet-based behavioral intervention of high risk MSM that included baseline collection of semen and a longitudinal follow up on a total 180 HIV-infected MSM that could be on or off ART.
For this study, we included a baseline semen samples from subset of 114 subjects who were receiving effective ART with blood plasma HIV <500copies/ml within three months before the seminal sample collection. Semen was collected and processed, as previously described [24, 25] . For each subject, potential infection from Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalum, and Trichomonas spp. were tested from urine, rectal and pharyngeal samples using transcription-mediated amplification (TMA) (Genprobe Aptima, San Diego CA). Active syphilis infection was evaluated by rapid plasma reagin titers (RPR), TPPA confirmatory testing and clinical history. Urinalysis was performed with a routine urine dipstick testing for leukocyte esterase; urine inflammation was defined as presence of leukocyte esterase of 1+ or greater. Blood CD4+ T lymphocyte subsets were measured by flow-cytometry (CLIA certified local laboratories), and HIV levels were quantified by the Amplicor HIV Monitor Test (Roche Molecular Systems Inc.).
All subjects completed a baseline computer assisted self-reported interview for sexual risk behavior, drug use and adherence to ART in the past month. The studies were conducted with appropriate written subject consent and were approved by the Human Research Protections Program at the University of California San Diego, Los Angeles Biomedical A c c e p t e d M a n u s c r i p t 
RNA Extraction from seminal plasma, and HIV quantification
HIV levels were measured in seminal plasma by first concentrating RNA from 500μL of seminal plasma with high-speed centrifugation (23,500xg at 4°C for 1 hour) after 1:1 dilution with phosphate buffered saline (PBS), as previously described [25] . Concentrated RNA was extracted using High Pure Viral RNA Kit (Roche) and cDNA was generated using the SuperScript III First-Strand Synthesis Kit (Invitrogen) with specific primer mf302 [26] .
HIV in seminal plasma was quantified by real-time PCR in an ABI 7900HT thermocycler (Applied Biosystems) [19, 25] . HIV RNA quantification standard was obtained from the DAIDS Virology Quality Assurance (VQA) Program [27] .
DNA Extraction from seminal plasma, and herpesvirus DNA quantification
Viral DNA was extracted from 200μl of seminal plasma using QIAamp DNA Mini Kit (Qiagen) per manufacturer's protocol. EDTA (50mM) was added to seminal plasma to inhibit DNase activity. Levels of different herpesviruses in semen were measured by realtime PCR in an ABI 7900HT thermocycler (Applied Biosystems, CA) [19, 25] .
Quantification standards for the different herpesviruses were obtained using plasmid preparations with known concentrations.
Statistics
Statistical analyses were performed using SAS (version 9.2). Viral load variables were transformed to logarithm base ten values. Non-normal data were either dichotomized A c c e p t e d M a n u s c r i p t 7 (undetectable/detectable) or ordinalized (undetectable/detectable; high versus low viral level with threshold at 4 log 10 copies/ml) as described previously [19] . Analyses were performed on the total study population of 114 subjects with HIV levels in blood <500 copies/ml, and on a subset of 100 subjects with HIV levels in blood <50 copies/ml.
Associations between seminal shedding of CMV (high level) or EBV (any level) with the presence of bacterial STIs, other viral co-infections, CD4 count, time on ART, and ART regimen were evaluated.
Results
Study participants' demographics and clinical data
HIV-infected participants (n=114) were high-risk MSM without clinical evidence of STIs who had a mean age of 44 years, receiving ART and with HIV <500 copies/ml in blood plasma within three month from semen collection (median time between semen collection and blood HIV level determination: 33 days, interquartile range (IQR): 14-70). One hundred subjects (88%) had HIV levels <50 copies/ml. The median time on ART at the time of semen collection was 2.5 years (IQR: 13.5 months-4.8 years), and the median CD4 count was 580 cells/uL (IQR: 532-628). For 112 subjects with available specific ART information, 76.8% were on a regimen including tenofovir; 39.3% were on a regimen including a nonnucleoside reverse transcriptase inhibitor (NNRTI); 55.4% were on a regimen including a protease inhibitor (PI); and 18.8% were on a regimen including an integrase inhibitor. Of the 21 subjects who were taking a regimen including an integrase inhibitor, 10 also included a PI, and 4 included a NNRTI. Self-reported levels of ART adherence during the last month were >90% for 99 (87%) of the subjects. Self-reported substance abuse (including marijuana, cocaine, amphetamines, club drugs, and opiates) was high at 34.2%, and methamphetamine use within one month from sample collection was reported by 13.6% of participants. Characteristics and demographics of the subjects are summarized in table 1.
Bacterial and viral genital infections
Eleven subjects (9.6% of the entire cohort) had detectable levels of HIV in semen, with a median of 2.1 log 10 RNA copies/ml among detectable samples (range 1.7-2.5), and 72 (63.2%) had at least one herpesvirus detected in their seminal plasma. These herpesviruses included CMV (frequency 49.1%, median detectable viral load of 4.3 log 10 DNA copies/ml, IQR 3.2-4.9), Epstein-Barr virus (EBV) (30.7%, 2.9 log 10 copies/ml, IQR 2.5-3.4), herpes simplex virus type 2 (HSV-2) (2.6% 5.1 log 10 copies/ml), human herpes virus type 6 (HHV-6) (7.0%, 3.3 log 10 copies/ml), human herpes virus type 7 (HHV-7) (8.8%, 3.2 log 10 copies/ml) and human herpes virus type 8 (HHV-8) (3.5%, 3.4 log 10 copies/ml) (figure 1). In contrast to our previous results on ART naïve subjects [19] , no HSV type 1 shedding was found in the semen of this cohort. Urethral, rectal or pharyngeal bacterial STIs were detected in 17 (14.9%) of the individuals, and non-specific urethritis in an additional 8 (7.0%) (Table 1) . Specifically, one subject had syphilis, five subjects had urethral STIs (three with M. genitalium and two with C. trachomatis), six patients had rectal STIs (two with C. trachomatis, three with N. gonorrhoea, and one subject co-infected with both C. trachomatis and N. gonorrhoea), and six patients had pharyngeal STIs (two with C. trachomatis, three with N. gonorrhea and one with trichomonas). All subjects were included in the study and treated for these infections after specimen collections. Subjects were all asymptomatic at the time of screening.
Key Predictors of isolated HIV seminal shedding on ART
Subjects with evidence of HIV replication in plasma while on ART (i.e. blood plasma HIV levels 50-500 copies/ml) had detectable levels of HIV in semen more frequently than subjects with <50 HIV copies/ml (35.7% versus 6.0%, FDR-adjusted p-value 0.08).
Neither the class of ART, the time on ART nor the self-reported pill-adherence were significantly associated with HIV shedding in semen. Also self-reported substance abuse was not associated with HIV seminal shedding.
Similar to our previous findings in ART-naïve HIV-infected MSM [19] , there was a trend for high-level CMV (>4 log10 DNA copies/ ml) and presence of EBV to be associated with detectable HIV seminal levels (tables 2 and 3). Specifically, 7 subjects (21.9%) with highlevel CMV replication in semen had concomitant HIV seminal shedding compared to 4 of those (4.9%) with no or low CMV shedding in semen (FDR-adjusted p-value=0.08), with a relative risk of 4.5 (95% CI, 1.4-14.2). A trend towards an increased frequency of detectable HIV seminal shedding was observed when comparing any level of CMV shedding to no CMV (14.3% versus 5.2%, p=0.12). For those subjects with both CMV and HIV detectable in semen, the mean CMV DNA level was 1 log 10 higher in semen compared to non-shedders, 3.9 versus 2.9 log 10 DNA copies/ml, but this difference was not statistically significant. Any detectable EBV shedding was also associated with HIV shedding in semen (22.9% HIV seminal shedding in subjects with concomitant EBV replication compared to 3.8% in those without EBV, FDR-adjusted p-value=0.06), but there was no evidence that higher EBV levels were associated with greater HIV shedding. In fact, for patients with HIV and EBV co-shedding, the levels of EBV DNA copies was lower in those shedding HIV in semen compared to those with no HIV shedding, 2.6 versus 3.1 log 10 DNA copies/ml (p=0.06). High-level CMV shedding in semen was also significantly associated with EBV shedding.
In a sub-analysis of the 100 subjects with HIV in blood of <50 copies/ml, of whom six had detectable HIV seminal levels, high CMV levels remained the only factor associated with 
Discussion
Since HIV in male genital secretions accounts for the majority of HIV transmission in both women and MSM [28] , it is crucial to understand the factors associated with increased seminal HIV replication in order to inform strategies to reduce sexual HIV transmission and the development of HIV drug resistance. Effective ART substantially reduces the HIV levels in blood and semen [1-4]; however, a significant number of subjects intermittently shed HIV in semen despite having suppressed levels in blood plasma [9] [10] [11] [12] .
In our study of sexually active, ART-treated MSM with blood plasma HIV levels <500 copies/ml, 11 (9.6%) had detectable HIV in seminal plasma at very low levels between 50 and 230 copies/ml. The prevalence of seminal HIV shedding falls within the range previously described in the literature (2%-48%) [9] [10] [11] [12] , depending on the characteristics of the observed population. Detectable levels of seminal HIV were present significantly more often in persons with plasma HIV between 50 and 500 copies/ml compared to those <50 copies/ml.
We previously described that seminal shedding of different herpesviruses (i.e. high-level CMV, EBV, HHV-8) was associated with increased levels of HIV within the genital tract of ART-naïve MSM. The present study aimed to investigate if this remains true as well in subjects receiving ART with suppressed HIV levels in blood plasma.
Consistent with previous studies [9] , we found a high prevalence of herpesviruses shedding in our treated cohort. Compared to our previous results on a similar cohort of ART-naïve HIV-infected MSM, we observed a lower frequency of seminal shedding for most herpesviruses, except for CMV and HHV-6. Specifically, in semen samples of ART- These observations suggest that ART initiation may reduce seminal shedding of many herpesviruses, but CMV DNA seminal shedding, in particular, remains highly prevalent in treated HIV-infected subjects. This finding is in contrast with other reports, showing decreased frequency of CMV replication after ART initiation [29, 30] , but these previous studies included subjects with lower CD4 counts and evaluated CMV replication in blood and not in semen.
Consistent with data from untreated subjects, we found that high-levels CMV replication (i.e. >4 log 10 DNA copies/ml) was associated with HIV seminal shedding even after the initiation of ART. We also found an association between EBV shedding and detectable HIV in semen, though no dose response was observed. Similar to our previous findings [19, 23] , CMV and EBV seminal shedding were positively associated with each other, and both viruses were associated with lower CD4 counts. Higher level CMV seminal shedding was positively associated with presence of pharyngeal STIs, with seminal HHV-8 and with use of PI-based ART regimens.
Interestingly, HIV seminal shedding in our cohort was not associated with non-specific genital inflammation or with any asymptomatic bacterial STIs. This may be a consequence of the relative low prevalence of urethral STIs in this asymptomatic cohort (3.5%).
However, this also suggests that CMV may be a more common precipitant of HIV shedding in semen than bacterial STIs during ART even in this high-risk MSM population. It is also possible that HIV seminal shedding is derived from the proximal genital tract rather than distally and therefore asymptomatic (non-ulcerative) STIs would not contribute directly to an increase in HIV seminal shedding. Of note, low levels of HIV in blood plasma between 50 and 500 copies/ml were associated with HIV seminal shedding, suggesting that a complete suppression of HIV blood levels may minimize the risk of sexual HIV transmission.
A recent study [9] observed that frequent, isolated seminal HIV shedding among 25 subjects was associated with increased compartmentalized immune activation within the genital tract, but could not find any association between detectable HIV levels and any of the evaluated factors, including CMV replication. We previously described that seminal CMV replication is positively associated with levels of immune activation in the male genital tract [18] , and our present study on a larger cohort, suggests that high-level CMV replication likely plays a role in HIV seminal shedding also in successfully treated HIV infected individuals.
This study has several limitations. Most importantly, despite including seminal samples from 114 different subjects, the low frequency of seminal shedding for HIV limited our power to find additional associations. Moreover, in this observational study, the causality of the associations cannot be definitively determined. We did not assess pre-and posttreatment levels in semen to address directly the impact of treatment in the same subject.
However, since successful treatment of HIV in this cohort did not influence the rate of CMV replication compared to untreated subjects in our previous cohort, CMV replication is likely driving HIV shedding and not vice-versa. Lastly, since we only included MSM in this study, it needs to be determined if these associations remain true also in genital secretion of heterosexual men and women since this could have an impact on management of serodiscordant couples trying to conceive children. 882 (406-1725) HIV RNA <500 copies/ml; n (%) 114 (100) HIV RNA <50 copies/ml; n (%) 100 (88) ≥90% adherence past month n (%) 99 (87) CD4+ cell counts/ul; mean (95% CI) 580 (532-628) Detectable HIV RNA in semen; n (%) 11 (9.6) HIV in semen log 10 copies/ml; median (range) 2.1 (1.7-2.5) 
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